High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm (Q44573499)

4 December 2017

title

High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm (English)

1 reference

4 December 2017

1 reference

1 reference

Richard G Wunderink

2

0 references

author name string

Lala M Dunbar

1

1 reference

4 December 2017

Michael P Habib

3

1 reference

4 December 2017

Leon G Smith

4

1 reference

4 December 2017

Alan M Tennenberg

5

1 reference

4 December 2017

Mohammed M Khashab

6

1 reference

4 December 2017

Barbara A Wiesinger

7

1 reference

4 December 2017

Jim X Xiang

8

1 reference

4 December 2017

Neringa Zadeikis

9

1 reference

4 December 2017

James B Kahn

10

1 reference

4 December 2017

language of work or name

English

0 references

publication date

28 August 2003

1 reference

Clinical Infectious Diseases

4 December 2017

published in

1 reference

4 December 2017

volume

37

1 reference

4 December 2017

issue

6

1 reference

4 December 2017

page(s)

752-760

1 reference

Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance Study in Ohio. The Community-Based Pneumonia Incidence Study Group

4 December 2017

cites work

1 reference

Community-acquired lower respiratory tract infections: etiology and treatment

21 January 2018

1 reference

Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance

21 January 2018

1 reference

Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis

21 January 2018

1 reference

Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients

21 January 2018

1 reference

Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials

21 January 2018

1 reference

A prediction rule to identify low-risk patients with community-acquired pneumonia

21 January 2018

1 reference

Epidemiology of clinically diagnosed community-acquired pneumonia in the primary care setting: results from the 1999-2000 respiratory surveillance program

21 January 2018

1 reference

Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the respiratory surveillance program study: microbiology from the medical office practice environment

21 January 2018

1 reference

Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999-2000.

21 January 2018

1 reference

Pharmacodynamics of 750 mg and 500 mg doses of levofloxacin against ciprofloxacin-resistant strains of Streptococcus pneumoniae

21 January 2018

1 reference

Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects

21 January 2018

1 reference

Comparison of side effects of levofloxacin versus other fluoroquinolones

21 January 2018

1 reference

Safety and pharmacokinetics of multiple 750-milligram doses of intravenous levofloxacin in healthy volunteers

21 January 2018

1 reference

Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicillin-clavulanate for complicated skin and skin-structure infections: a randomized, open-label trial

21 January 2018

1 reference

Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: A multicenter, prospective, randomized, open-label study

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1086/377539

1 reference

4 December 2017

1 reference